Summary & Overview
HCPCS J0699: Injection, cefiderocol, 10 mg
HCPCS Level II code J0699 identifies the injection form of cefiderocol, specified as 10 mg per billing unit. Cefiderocol is a parenteral siderophore cephalosporin used to treat certain serious Gram-negative infections and its distinct HCPCS code supports billing and utilization tracking for hospital outpatient departments and infusion settings. Nationally, accurate capture of this code matters for antimicrobial stewardship reporting, inventory management, and payer reimbursement workflows.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks and policy context for billing and coverage practices, an overview of clinical indications tied to the drug class, and notes on sites of service where J0699 is most commonly used. The publication outlines common modifier usage and administrative considerations where available, while identifying areas where data is not provided.
This summary provides clinicians, coders, and revenue cycle managers with concise information on what J0699 represents, the care settings in which it is billed, and the payer landscape relevant to national billing practices for intravenous antimicrobial therapy. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0699 represents the injection formulation of cefiderocol in a unit of 10 mg. This HCPCS code describes a parenteral antimicrobial agent administered by injection.
Service Type: Injection (parenteral medication administration)
Typical Site of Service: Hospital outpatient departments, infusion centers, and other clinical settings where intravenous or intramuscular antimicrobial administration occurs.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A hospitalized adult patient with a confirmed or suspected multi-drug resistant Gram-negative bacillus infection (for example, complicated urinary tract infection, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infection) receives intravenous cefiderocol as targeted antimicrobial therapy. The decision to use J0699 (injection, cefiderocol, 10 mg) follows microbiology data showing susceptibility to cefiderocol or empiric use when other agents are contraindicated. The typical workflow: infectious disease consultation or hospitalist documents indication and dose; pharmacy compounds the vial(s) and records lot numbers; nursing administers the infusion via peripheral IV or central venous catheter over the manufacturer-recommended infusion time; observation for infusion reaction and therapeutic response occurs during and after dosing; documentation includes dose, route, infusion time, lot number, and any applicable modifiers for billing (for example, modifier JW to report discarded drug or QX for services performed by a certified registered nurse anesthetist when applicable). Typical site of service is an inpatient acute care hospital or an acute inpatient rehabilitation setting; outpatient infusion center or skilled nursing facility may also administer cefiderocol for outpatient parenteral antibiotic therapy (OPAT). Patient scenario example: a 67-year-old with chronic kidney disease and ventilator-associated pneumonia due to carbapenem-resistant Pseudomonas aeruginosa is started on cefiderocol with renal-adjusted dosing and daily nursing documentation of renal function and clinical response.
Coding Specifications
| Modifier | Description |
|---|